Issa Lo
Acute Care · Frederick, MDNPI 1013546100
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $553 and has fallen 56.2% since, to $243 in 2025.
Across 22 payments — averaging $77.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$311
- Dexcom, Inc.$212
- GSK$152
- Biogen$149
- AbbVie$146
- Amgen$115
- plus $620 from 9 others
What the payments were for
- Food & beverage$1,705100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $311 |
| Dexcom, Inc. | 2 | $212 |
| GSK | 2 | $152 |
| Biogen | 2 | $149 |
| AbbVie | 2 | $146 |
| Amgen | 1 | $115 |
| Daiichi Sankyo Inc. | 1 | $108 |
| Phathom Pharmaceuticals, Inc. | 1 | $98 |
| Sumitomo Pharma America, Inc. | 1 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Axsome Therapeutics, Inc. | 1 | $87 |
| Amarin Pharma, Inc. | 1 | $67 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Gilead | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$115
- DEXCOM STELO GLUCOSE BIOSENSOR$115
- Repatha$115
- BREZTRI$112
- INJECTAFER$108
- FASENRA$105
How this compares
$1,705 in reported general payments places this provider in the 85th percentile of 502 acute care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $15,365 |
| MyrbetriqMirabegron | 12 | $11,791 |
| RytaryCarbidopa/Levodopa | 12 | $9,609 |
| Praluent PenAlirocumab | 12 | $6,453 |
| Methenamine Hippurate | 50 | $3,708 |
| Omeprazole | 45 | $1,354 |
| Amlodipine Besylate | 49 | $962 |
| Donepezil Hcl | 13 | $869 |
| Colestipol Hcl | 13 | $810 |
| Lactulose | 29 | $752 |
| Potassium Chloride | 28 | $724 |
| ClopidogrelClopidogrel Bisulfate | 12 | $719 |
| Pravastatin Sodium | 31 | $683 |
| Sertraline Hcl | 19 | $606 |
| Divalproex Sodium | 13 | $600 |
Paid to pharmacies, not to this prescriber.
Other acute care in Frederick
- Kristin DeelyFrederick$2K
- Ingrid HalvorsonFrederick$2K
- Paige GriffithBaltimore$106K
- Amanda ReaPerry Hall$65K
- T Nicole KelleyBaltimore$46K
- Amy GoodrichBaltimore$27K
- Rama AnthonyBaltimore$20K
- Susan HuppmannBaltimore$16K
- Eleanor DunlapBaltimore$11K
- Tierra AndersonTakoma Park$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.